Logo

AMIX

Autonomix Medical, Inc. Common Stock

AMIX

Autonomix Medical, Inc. Common Stock • NASDAQ
$1.07 ▲ 0.94% (+0.01)
Market Cap $5.51 M
52w High $5.25
52w Low $0.69
Dividend Yield 0%
P/E -0.24
Volume 243.23K
Outstanding Shares 5.15M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $0 $7.532M ▲ $-7.451M ▼ 0% $-1.38 ▼ $-7.449M ▼
Q1-2026 $0 $3.421M ▲ $-3.337M ▼ 0% $-1.07 ▲ $-3.334M ▼
Q4-2025 $0 $3.204M ▲ $-3.191M ▼ 0% $-1.81 ▼ $-3.097M ▼
Q3-2025 $0 $2.747M ▼ $-2.712M ▲ 0% $-1.46 ▲ $-2.62M ▲
Q2-2025 $0 $2.836M $-2.807M 0% $-2.47 $-2.719M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $7.477M ▼ $7.932M ▼ $1.487M ▼ $6.445M ▼
Q1-2026 $8.589M ▼ $8.997M ▼ $1.965M ▲ $7.032M ▼
Q4-2025 $9.136M ▼ $9.806M ▼ $1.707M ▼ $8.099M ▼
Q3-2025 $11.823M ▲ $11.952M ▲ $2.245M ▼ $9.707M ▲
Q2-2025 $5.155M $5.371M $2.343M $3.028M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $-3.337M $-2.668M ▼ $0 $2.121M ▲ $-547K $-2.668M ▼
Q1-2026 $-3.337M ▼ $-2.604M ▼ $0 ▲ $2.057M ▲ $-547K ▲ $-2.604M ▼
Q4-2025 $-3.191M ▼ $-2.509M ▼ $-4K ▲ $-174K ▼ $-2.687M ▼ $-2.513M ▼
Q3-2025 $-2.713M ▲ $-2.301M ▼ $-5K ▼ $8.974M ▲ $6.668M ▲ $-2.306M ▼
Q2-2025 $-2.807M $-1.596M $0 $0 $-1.596M $-1.596M

Five-Year Company Overview

Income Statement

Income Statement Autonomix is still a pure development‑stage company with no product revenue yet. The income statement mainly shows research, development, and corporate costs, which create ongoing losses. Those losses are relatively small in absolute dollar terms but meaningful given the company’s tiny size. The pattern so far is consistent with an early medical‑device startup: spending to build and test the technology while commercial income is still years away. Future results will likely stay uneven and loss‑making until clinical trials progress and any product approvals or partnerships materialize.

Balance Sheet

Balance Sheet The balance sheet is very simple and very small. It is almost entirely made up of cash, with no reported debt and equity roughly matching the cash position. This is typical for a recently listed, early‑stage medtech company that has raised capital but has not yet built up physical assets or inventory. The clean, debt‑free structure is a positive, but the limited asset base also underscores how dependent the company will be on future capital raises or partnerships as its trials and operations expand.

Cash Flow

Cash Flow Cash flow shows a steady cash burn from operations and essentially no spending yet on major equipment or facilities. In other words, money is mainly going out to fund research, clinical preparation, and corporate overhead, with nothing coming in from product sales. The burn rate currently looks modest, but as trials scale up, cash needs could increase. With no internal cash generation, the business remains reliant on external funding sources to keep moving its pipeline forward.

Competitive Edge

Competitive Edge Autonomix is trying to build a niche in nerve‑targeted therapies with a very distinctive, catheter‑based technology. Its main edge today is not market share—because it has no commercial product yet—but rather a large and growing patent portfolio and a first‑mover position in transvascular diagnosis and treatment of peripheral nerves. If the technology continues to work as described, it could set the company apart from more traditional pain and neuromodulation approaches. At the same time, it operates in a field where large, well‑funded device companies could eventually become competitors or partners, and its platform still has to prove itself in larger clinical trials and real‑world use. The moat is therefore mostly intellectual property and technical uniqueness, not yet commercial entrenchment.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of the Autonomix story. The company’s platform is built around a tiny microchip on a catheter that can detect nerve signals with very high sensitivity from inside blood vessels, then use radiofrequency energy to selectively disable overactive nerves and confirm the effect. This “sense, treat, and verify” concept is a step beyond many current neuromodulation tools, which often either sense or treat but not both in such an integrated, minimally invasive way. Early proof‑of‑concept work in pancreatic cancer pain has shown encouraging signs, and management is positioning the same platform for a long list of nerve‑related conditions, from other cancer pain to hypertension and chronic pain syndromes. However, most of this pipeline is still conceptual or early‑stage, so there is significant scientific, clinical, and regulatory risk ahead before any of these ideas turn into approved, widely adopted products.

Summary

Autonomix is an early, high‑risk, high‑potential medical device developer. Financially, it is a small, pre‑revenue company burning cash to advance its platform, with a clean but thin balance sheet and a need for ongoing external funding. Strategically, its strength lies in a novel nerve‑sensing and ablation technology backed by a broad patent estate and aimed at large, underserved markets like cancer pain and cardiovascular conditions. The company’s future will largely hinge on the success of upcoming clinical trials, regulatory submissions, and its ability to convert technical promise into real‑world adoption, all of which carry considerable uncertainty. For now, Autonomix is best understood as an emerging, innovation‑driven medtech story rather than an established operating business.

NEWS

November 26, 2025 · 8:45 AM UTC

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

Read more

November 18, 2025 · 8:30 AM UTC

Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules

Read more

October 24, 2025 · 9:00 AM UTC

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference

Read more

October 16, 2025 · 9:15 AM UTC

Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit

Read more

October 9, 2025 · 8:45 AM UTC

Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

Read more